Please login to the form below

Not currently logged in
Email:
Password:

Positive opinion for Bayer drug

The European Committee for Medicinal Products for Human Use has recommended the approval of rivaroxaban, an anticoagulant being developed and researched by Bayer Schering Pharma UK
The European Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of rivaroxaban, an anticoagulant being developed and researched by Bayer Schering Pharma UK.

The company hopes that the European Commission (EC) will grant final approval for the drug within the next few months providing marketing authorisation for all 27-member states. Rivaroxaban, which is known by its brand name Xarelto, is an anticoagulant developed for the prevention of venous blood clots - deep vein thrombosis (DVT) and pulmonary embolism (PE) - in patients undergoing elective hip or knee replacement surgery.

Recommendation for the drugs approval came just nine months after Bayer Schering Pharmaís submission and was based on results for the phase III Record clinical trials into rivaroxaban. According to Bayer Schering Pharma, the studies, which involved 10,000 patients undergoing elective hip or knee replacement surgery, demonstrated the drugs effectiveness over other medicines.

"The prevention and treatment of thrombosis remains a challenge for patients requiring chronic therapy. The availability of agents such as rivaroxaban has the potential for a substantial impact on patient care," said Ajay Kakkar, professor of surgical sciences at Barts and the London School of Medicine.

28th July 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Clark Health Communications

Clark Health Communications (CHC) is an independent, award-winning health and medical communications agency. Our collaboration with experts and advocates enhances...

Latest intelligence

NEW EU DATA PROTECTION REGULATION POISED TO CHANGE DATA PRIVACY LANDSCAPE
NEW EU DATA PROTECTION REGULATION POISED TO CHANGE DATA PRIVACY LANDSCAPE The bold digital clock featured on the EUGDPR (EU General Data Protection Regulation)1 website indicates – to the second...
Health knowledge: Why is it so important?
Health knowledge plays an important role in population health, but by itself is rarely enough to prompt a change in the behaviours that cause the risks....
Personas: a top tool for personalising pharma marketing campaigns
Healthcare customers are calling for greater personalisation in care from providers. Here, we explain why personas are the top tool for ensuring your brand meets this need efficiently and effectively....

Infographics